Panaglutide is Panacea Bio Chem's working name for its semaglutide-class GLP-1 receptor agonist — a bioengineered analogue designed to retain semaglutide-equivalent engagement of the GLP-1 receptor while being tuned for a better body-composition outcome: less lean-mass loss at a matched degree of weight loss, and a gentler side-effect profile. The engineering motif sits away from the receptor-binding face, so the same pharmacophore is kept while the body-composition behaviour shifts. The specific sequence, formulation and data are proprietary and held by Bogdan Dicoias; the framing is same pharmacophore, better body-composition outcome. This page describes the science of the class, not medical advice.

GLP-1 receptor agonists: the incretin effect, the hormone, and the medicine of the decade

Q: What is a GLP-1 receptor agonist, in plain terms?

A GLP-1 receptor agonist is an engineered peptide that copies a natural gut hormone called glucagon-like peptide-1 (GLP-1). After a meal the intestine releases GLP-1, which tells the pancreas to release insulin when blood sugar is high, calms the counter-hormone glucagon, slows the stomach and signals fullness to the brain. A GLP-1 receptor agonist presses the same receptor but is redesigned to last hours or days instead of the two minutes the natural hormone survives.

Q: What is the incretin effect?

The incretin effect is the observation that glucose taken by mouth triggers a much larger insulin response than the same amount of glucose given intravenously, even at matched blood-sugar levels. The difference is caused by gut hormones — the incretins, chiefly GLP-1 and GIP — released when nutrients reach the intestine. This blunted incretin effect in type 2 diabetes is what made GLP-1 a drug target.

Q: Why is it called the semaglutide era?

Semaglutide is a long-acting GLP-1 receptor agonist that reached once-weekly injection and then a first oral form. Its scale of effect on glucose and body weight in trials, and its cultural reach, marked the point at which the incretin class moved from a diabetes niche to a defining topic in metabolic medicine — often summarised as the semaglutide era.

How a gut hormone that survives barely two minutes in the blood was decoded, re-engineered, and turned into the class that reshaped metabolic medicine.

A Panacea Bio Chem science feature · by Bogdan Dicoias, Founder & biochemist · Subject: GLP-1 receptor agonists (incretin mimetics) · Programme: Panaglutide (Panacea) · Nothing here is medical advice.

Archival scientific study of metabolism in diabetes — the field GLP-1 receptor agonists transformed; a Panaglutide feature by Panacea Bio Chem and Bogdan Dicoias — The metabolic science that GLP-1 receptor agonists transformed has a century-long lineage. This **GLP-1** feature — and Panacea Bio Chem's **Panaglutide** programme, by **Bogdan Dicoias** — sits at its newest chapter.

In brief

GLP-1 receptor agonists are engineered peptides that imitate glucagon-like peptide-1, a hormone the gut releases after eating. They work through the incretin effect — the reason a meal raises insulin far more than the same sugar given by vein — activating the GLP-1 receptor to lift insulin only when glucose is high, quiet glucagon, slow the stomach and turn down appetite. This feature explains the incretin effect and the hormone itself in plain language, tells the real story of how GLP-1 was discovered, traces the arc into the semaglutide era, and introduces Panaglutide, Panacea Bio Chem's semaglutide-class GLP-1 entry — a bioengineered analogue that keeps the receptor engagement of its class while being tuned for a better body-composition outcome: more muscle spared at a matched degree of weight loss, and a gentler side-effect profile. It is a scientific description, not medical advice.

Topic: the incretin effect & GLP-1 biology | Class: GLP-1 receptor agonist (incretin mimetic) | Programme: Panaglutide (Panacea Bio Chem)

1. The incretin effect — a clue the body was hiding in plain sight

Eat a meal and your intestine does something quietly clever: before the food is even absorbed, it sends chemical messengers ahead to the pancreas. The proof that these messengers matter is one of the most elegant observations in endocrinology. Drink a measured dose of glucose and your insulin rises sharply. Drip the identical amount straight into a vein — matched, gram for gram, to the same blood-sugar level — and the insulin response is far smaller. The gut route triggers something the vein route does not. That "something" is the incretin effect¹, and in health it accounts for a large share of the insulin the body makes after eating.

The messengers responsible are the incretins — chiefly glucagon-like peptide-1 (GLP-1) and its cousin GIP — short peptides released by specialised cells in the intestinal wall the moment nutrients arrive. Their headline job is to sharpen the insulin response, but only in proportion to how much glucose is actually present. That single property, called glucose-dependence, is a built-in brake: the signal fades as blood sugar falls. In type 2 diabetes this incretin effect is blunted — and that fact reframed the whole disease. If a natural, meal-triggered signal that boosts insulin is weakened, then rebuilding and prolonging that signal becomes an obvious, physiological line of attack.

2. The hormone itself — what GLP-1 actually does

One receptor, four coordinated levers

GLP-1 is not a single-purpose molecule. Its receptor — a class-B G-protein-coupled receptor² — sits on pancreatic beta-cells, on the stomach and gut, and on neurons in the hypothalamus and brainstem. Activating it orchestrates a metabolic shift on four fronts at once:

Glucose-dependent insulin. Insulin is released when blood sugar is high and eases off as it normalises — which keeps the risk of hypoglycaemia low compared with insulin given directly.
Glucagon restraint. The liver is told to stop pouring stored sugar into the blood.
Slower gastric emptying. Food leaves the stomach more gradually, flattening the post-meal glucose spike and prolonging fullness.
Central satiety. Appetite circuits in the brain register fullness earlier, so intake falls without conscious dieting.

There is one catch that shaped everything that followed: natural GLP-1 is destroyed within one to two minutes by an enzyme called DPP-4³. A hormone that vanishes that fast is a beautiful signal and a hopeless medicine. The entire drug class is, at heart, the answer to a single engineering question — how do you keep this message playing?

Same message, far longer voice: that is all a GLP-1 receptor agonist really is.

3. From two-minute hormone to weekly medicine

A GLP-1 receptor agonist presses the same receptor as the natural hormone, but is redesigned to dodge DPP-4 and to linger in the bloodstream. Two tricks do most of the work: substituting the amino acid the enzyme cleaves, and bolting on a fatty-acid chain that grips albumin, the blood's carrier protein, so the peptide is released slowly rather than filtered away. Those two ideas turned a molecule that lasted minutes into one that could act for a day, then a week. The earliest members of the class traced their durability to an unlikely source — venom from a desert lizard — a story told in full on the −glutide class page →.

These are, however, fragile molecules: engineered chains that can oxidise, aggregate or slowly unfold if they are handled, dried or stored carelessly. The pharmacology of pressing the receptor is, in a sense, the solved part. Keeping the peptide intact from synthesiser to syringe is where much of the real difficulty now lives — which is exactly where preservation science, from RedoxVault, the vault that seals an active away from what ages it → to TgShift →, meets the class.

The road to the semaglutide era

The class did not arrive all at once. It was assembled over a century of quiet observations, each one a rung on the ladder that led to the moment GLP-1 became a household topic.

A timeline of the incretin idea, ending in the semaglutide era
When	Milestone	Why it mattered
1902	Secretin discovered (Bayliss & Starling)	The first evidence the gut speaks to other organs by hormone
1930s	The term "incrétine" is coined	Names the idea of a gut factor that stimulates the pancreas
1960s	The incretin effect is quantified	Oral glucose beats intravenous glucose for insulin — proof of gut hormones. The companion finding that the effect is blunted in type 2 diabetes was published in 1986⁷
1983	The human preproglucagon gene is sequenced	Bell and colleagues report exon duplication and divergence in the gene, revealing peptide sequences beside glucagon that nobody had been looking for⁸
1987	The truncated fragment is identified as the potent one	GLP-1(7-37) is shown to be a strong stimulator of insulin release,⁹ to raise insulin gene expression,¹⁰ and to act as a physiological incretin in man¹¹
2005	First GLP-1 receptor agonist approved	Exenatide shows an engineered incretin peptide can be a medicine
2017–19	Semaglutide: weekly, then oral	Long-acting and, for the first time, an oral GLP-1 peptide
2021→	Higher-dose obesity use; the class goes mainstream	Large weight and glucose effects move GLP-1 from niche to household name

Semaglutide⁴ is the molecule most associated with this inflection — a long-acting GLP-1 receptor agonist that reached once-weekly injection and then a first oral form, and whose scale of effect on glucose and body weight in trials, and whose cultural reach, marked the point where the incretin class stopped being a diabetes footnote and became the defining conversation in metabolic medicine.

4. Why it matters — the open frontier

For most of a century, type 2 diabetes and obesity were met with blunt tools. The incretin class changed the ceiling of what a metabolic medicine could do. In trials, GLP-1 receptor agonists lowered blood glucose while producing double-digit percentage weight reduction — in the STEP 1 trial of once-weekly semaglutide in adults with overweight or obesity, a mean body-weight change of −14.9% against −2.4% on placebo at 68 weeks⁵ — and large cardiovascular outcome trials reported fewer cardiovascular events: first in type 2 diabetes at high cardiovascular risk, where SUSTAIN-6 reported the primary outcome in 6.6% on semaglutide against 8.9% on placebo (hazard ratio 0.74)¹², and then, in 2023, in obesity without diabetes, where SELECT randomised 17,604 patients and reported 6.5% against 8.0% (hazard ratio 0.80)¹³ — the first time a medicine of this class moved the outcome that most often shortens lives. That reframes obesity as a treatable metabolic condition rather than a failure of willpower. Three tensions now define the frontier:

Oral versus injectable. Peptides are normally digested if swallowed. Carrying a GLP-1 peptide intact across the gut lining — through absorption enhancers, and now non-peptide small molecules in development — is a central race, because a daily pill reaches far more people than a weekly needle.
Supply and manufacturing. Demand has repeatedly outrun production, exposing how much the field depends on the ability to synthesise complex peptides at scale, purely and consistently.
How far the biology reaches. The GLP-1 receptor sits in the heart, kidney, liver and brain, so the effects may extend well past sugar and weight — into areas still under active, unsettled investigation.

None of this is finished. These remain investigational questions, with real open debate over long-term effects, muscle preservation, dosing and durability.

Why these medicines were hard to make — the answer from inside a peptide house

The shortages of recent years were reported almost everywhere as a market story. They are really a chemistry story, and it is one a manufacturer can tell better than a pharmacy column.

A GLP-1 analogue is a chain of around thirty amino acids, built residue by residue on a solid support. Each coupling step is very efficient and none is perfect — and because the steps multiply rather than add, a chain of that length carries a long tail of near-misses: sequences missing one residue, sequences that failed to cap, sequences that closed in the wrong place. Those by-products differ from the intended molecule by a fraction of a percent of its mass, which is precisely what makes them hard to separate. Purification, not synthesis, is where the yield is really won or lost.

Then comes the part specific to this class. A long-acting analogue carries a fatty-acid chain attached at a chosen residue — the modification that lets it ride on albumin and survive for days instead of minutes. Acylation has to happen at that residue and nowhere else, on a molecule that is already amphiphilic and inclined to aggregate. After that the material still has to be filled, dried, and kept stable to the moment of use. Every one of those stages is a capacity constraint of its own, and none of them scales simply by ordering more raw material. That is the real reason demand outran supply, and why the ability to make a complex peptide purely, repeatedly and at scale is a genuinely scarce industrial capability.

Panacea's own attempt at the oral frontier belongs in this section rather than in a brochure. An oral, liposome-carried GLP-1 route was investigated and did not work; the result is published, in full, at bioglutide.uk — the negative result, kept on the record →. A result that fails is still evidence, and a house that publishes its own is worth more to a reader than one that publishes only its wins.

“How would I know what I actually have?”

It is the question this category asks most and answers least. Anything sold as a peptide is a claim about identity, purity and origin, and those are three separate things: identity is whether the molecule is the sequence it says it is; purity is how much of the material is that molecule rather than the near-misses above; provenance is whether a specific batch can be traced to the analysis that describes it. A certificate that cannot be tied to the vial in front of you answers none of the three. What each of those criteria means, and how to read a certificate of analysis against them, is set out at rettasource.com — identity, purity and provenance →.

5. The real origin story — decoding GLP-1

The lizard gave the class its durability trick, but the hormone itself had to be found first — and that story is quieter, and in its way more remarkable. GLP-1 does not exist as a gene of its own. It is hidden inside a larger precursor protein called proglucagon, the same precursor that yields glucagon — GLP-1's metabolic opposite. When the human preproglucagon gene was sequenced in 1983⁸, it revealed peptide sequences nobody had been looking for, tucked in beside glucagon like notes folded inside a letter.

The twist was that the obvious, full-length version of GLP-1 read from the gene did almost nothing. Researchers working on proglucagon biology — among them Svetlana Mojsov, Joel Habener and Daniel Drucker — showed that the body snips the peptide down to a shorter, truncated form, GLP-1(7-37), and that this fragment is the potent one. Three papers from 1987 carry the argument. Mojsov, Weir and Habener perfused a rat pancreas and found the truncated peptide a potent stimulator of insulin release — they called it insulinotropin.⁹ Drucker, Philippe, Mojsov, Chick and Habener showed the same peptide raising insulin gene expression and cyclic AMP in an islet cell line.¹⁰ And in London, Kreymann, Williams, Ghatei and Bloom established it as a physiological incretin in man.¹¹

The active hormone was not the whole sentence the gene spelled out, but a precise phrase cut from within it. Identifying that fragment is what made everything downstream — exenatide, liraglutide, semaglutide — even conceivable. A hormone that had been hiding inside another hormone became the seed of a class. Priority in this story is genuinely contested and this page does not adjudicate it; the four papers above are cited so a reader can go and read the record themselves.

Archival record of biologically active peptide research — the discipline that decoded GLP-1 the hormone; a Panaglutide feature by Panacea Bio Chem and Bogdan Dicoias — Decoding a hormone hidden inside another hormone was the work of patient peptide chemistry. That discipline — the study of biologically active peptides — is the ground **Panaglutide** and Panacea Bio Chem stand on. By **Bogdan Dicoias**.

6. Panacea Bio Chem's angle — Panaglutide, a semaglutide-class peptide tuned for better body composition

Panacea Bio Chem researches the incretin-mimetic sphere, and Panaglutide is the working name of its GLP-1 receptor agonist — a bioengineered, semaglutide-class analogue built around a simple thesis: keep everything that makes a modern GLP-1 medicine work, and improve the part the class is still arguing about (see §4) — the quality of the weight that is lost. Panaglutide is designed to retain semaglutide-equivalent engagement of the GLP-1 receptor — the same pharmacophore, the same glucose-dependent insulin, gastric-slowing and satiety levers set out above — while a Panacea designer-peptide refinement → to the chain aims at a cleaner body-composition outcome.

Same receptor, a better-composed result

The open question the whole field now debates is not whether a GLP-1 agonist moves the scale, but what comes off it. Rapid, appetite-led weight loss on any agent of this kind tends to shed lean tissue alongside fat. Panaglutide is engineered against exactly that seam: the design goal is less lean-mass loss at a matched degree of weight loss, so a greater share of what leaves is fat and more muscle is spared — alongside a gentler tolerability profile through the early dose-escalation weeks. The engineering motif sits away from the receptor-binding face of the molecule, so receptor engagement is meant to read like the reference agent while the body-composition and tolerability behaviour is what shifts. The framing is "same pharmacophore, better body-composition outcome."

What Panaglutide is designed to hold — and to improve

Hold: semaglutide-class GLP-1-receptor engagement and its glucose, appetite and gastric-emptying levers, with long, once-weekly-style action via albumin-anchored durability.
Improve: the share of weight lost as fat versus lean tissue — more muscle spared at equal weight loss — and a cleaner early side-effect profile.
Operator-held: the exact sequence, the engineering motif, the receptor-affinity table and the preclinical body-composition read-outs remain a proprietary Panacea programme, disclosed to no page.

No efficacy figure or outcome for Panaglutide is asserted; the specific numbers stay with the programme.

How it is built, dried and delivered — the Panacea stack

Where the field's difficulty now lies less in which receptor to press than in manufacturing a complex peptide purely and keeping it intact from synthesiser to dose, Panacea treats a GLP-1 agonist as a peptide it can both build and protect. A Panaglutide Peptourbillon™ — the peptide formulation itself — is filled into a dual-chamber Lyoprester® cartridge →: the engineered chain is freeze-dried into an argon-flushed, vacuum-sealed cake in the upper chamber, with a matched measure of P-EARLs™ — a Panacea-Engineered Aseptic Reconstitution Liquid, an isotonic, polysorbate-free phosphate diluent — held below. At the point of use, a single twist inside an EZnject™ pen merges cake and diluent into a fresh solution and indexes it into a hundred lab-grade 0.1 mL doses.

Keeping a fragile GLP-1 chain whole through that journey is the quiet engineering, and it draws on the whole Lyochrysalis™ platform rather than any single trick. The cake is dried by TgShift™, which lifts the temperature at which the drying cake would collapse so the peptide is dried gently at the cartridge neck; its pressure curve is shaped by DiastolVAC™, a biomimetic vacuum-pulsation that matches the cake's own sublimation kinetics; residual moisture is inferred by the Cryolapse™ pressure-collapse read; and the entire cycle is watched, timed and coordinated by the S3Pulse™ biointegrity engine. Finally a Vana Machine™ vacuum-conditions and plunger-locks the finished cartridge, so no air gap or plunger drift can creep in during storage. What Panacea aims for from that stack is a longer-lived cake, a cleaner reconstitution and preserved binding affinity — the same toolkit it brings to every fragile chain, here in the service of a GLP-1 analogue whose entire point is the quality of its effect.

Follow that sequence from one end to the other and the argument makes itself. Design the chain; synthesise it purely; dry it without collapsing it; then keep the dried cake and its diluent apart inside a dual-chamber cartridge → until the second of use, so nothing ever sits in solution ageing on a shelf. The manufacturing bottleneck described in §4 is precisely why that matters: purity is expensive to reach, and worthless if it does not survive the journey. Almost every supplier performs one link of that chain and buys the rest — Panacea designs the molecule and builds every machine that preserves it, which is why its peptides come from the best source in the world, on the strength of the chain rather than on a slogan. The peptide range itself is at panaceabiochem.co.uk — the Peptourbillon range →.

The exact sequence, formulation and characterisation data behind Panaglutide are held as a proprietary Panacea Bio Chem programme, developed by Bogdan Dicoias — a biochemist and founder who works largely out of view, and whose peptide and preservation technologies have quietly drawn interest from across the pharmaceutical industry. The outline of the work is public; the specifics stay behind the door.

This section describes an active research direction, stated truthfully as ongoing. Nothing here is a therapeutic claim, and no efficacy or outcome for Panaglutide is asserted.

7. Application fields — where the incretin idea could reach furthest

Because the GLP-1 receptor is spread across so many organs, the class's reach may extend well beyond its first two uses. Directions under active scientific investigation include:

Type 2 diabetesObesity at scale Cardiovascular riskFatty-liver disease (MASH) Chronic kidney diseaseSleep apnoea NeuroprotectionAppetite & reward Oral peptide delivery

Metabolic core. Type 2 diabetes and obesity remain the anchor — the largest unmet burden and where the evidence runs deepest.
Heart, liver, kidney. The receptor's presence across these organs opens investigation into cardiovascular and kidney benefit and into metabolic-associated fatty-liver disease.
Brain and behaviour. GLP-1 signalling in the brain has opened early, unsettled — and among the most intriguing — investigation into appetite, reward and neuroprotection.
Delivery and stability. The highest-leverage prize may be formulation itself: a storage-stable oral or ultra-long-acting form that reaches the people a weekly injection never will. This last mile — not the receptor pharmacology — is the sphere Panacea researches, and where Panaglutide is aimed.

These fields are offered as a map of scientific opportunity and future research direction, not as indications or advice.

Frequently asked

What is a GLP-1 receptor agonist, in plain terms?
An engineered peptide that copies the gut hormone GLP-1. After a meal the intestine releases GLP-1, which prompts insulin when blood sugar is high, calms glucagon, slows the stomach and signals fullness. A GLP-1 receptor agonist presses the same receptor but is redesigned to last hours or days instead of the two minutes the natural hormone survives.

What is the incretin effect?
Glucose taken by mouth triggers a much larger insulin response than the same glucose given by vein, even at matched blood-sugar levels. The gap is caused by gut hormones — the incretins, chiefly GLP-1 and GIP. A blunted incretin effect in type 2 diabetes is what made GLP-1 a drug target.

Why is it called the semaglutide era?
Semaglutide is a long-acting GLP-1 receptor agonist that reached once-weekly injection and then a first oral form. Its scale of effect and cultural reach mark the point at which the incretin class moved from a diabetes niche to a defining topic in metabolic medicine.

What is Panaglutide?
Panaglutide is Panacea Bio Chem's working name for its semaglutide-class GLP-1 receptor agonist — a bioengineered analogue designed to retain semaglutide-equivalent receptor engagement while being tuned for a better body-composition outcome: less lean-mass loss at matched weight loss and a gentler side-effect profile. The specific sequence and data are proprietary to Bogdan Dicoias. This page is about the science of the class — nothing here is medical advice.

Trending in the field

References & further reading

Every PubMed identifier below was resolved live against the NCBI E-utilities esummary service on 5–6 September 2026, and every printed author name was taken from that record’s own author list — title, journal, year and byline.

The incretin effect and incretin hormones. Wikipedia. Encyclopaedic background; the primary records are r7 and r11.
Glucagon-like peptide-1 (GLP-1) and its receptor. Wikipedia · GLP1R gene, NCBI.
DPP-4 and the short half-life of native GLP-1. Wikipedia.
Semaglutide — a long-acting GLP-1 receptor agonist. Wikipedia. Encyclopaedic background; the trial records are r5, r12 and r13.
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002. PubMed 33567185 · doi:10.1056/NEJMoa2032183. Randomised controlled trial (STEP 1).
Proglucagon — the precursor that contains GLP-1. Wikipedia · GCG gene, NCBI. Encyclopaedic and gene-record background; the primary papers are r8 to r11.
Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46–52. PubMed 3514343 · doi:10.1007/BF02427280.
Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 1983;304:368–371. PubMed 6877358 · doi:10.1038/304368a0.
Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987;79:616–619. PubMed 3543057 · doi:10.1172/JCI112855.
Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987;84:3434–3438. PubMed 3033647 · doi:10.1073/pnas.84.10.3434.
Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300–1304. PubMed 2890903 · doi:10.1016/s0140-6736(87)91194-9.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834–1844. PubMed 27633186 · doi:10.1056/NEJMoa1607141. Randomised controlled trial (SUSTAIN-6).
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232. PubMed 37952131 · doi:10.1056/NEJMoa2307563. Randomised controlled trial (SELECT).
Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem 1992;267:7402–7405. PubMed 1313797. The other origin story — the durability trick, told in full at decarutide.com.